NCT00287118View on ClinicalTrials.gov

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

October 27, 2004

Primary Completion Date

May 30, 2006

Study Completion Date

May 30, 2006

Conditions
Candidates for Systemic Therapy for PsoriasisPsoriasis
Interventions
DRUG

Efalizumab

Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.

Trial Locations (1)

Unknown

Medical Information Switzerland, Geneva

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00287118 - A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter